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ABSTRACT 
Objective: Arteriovenous Malformations (AVMs) have an inherent capacity to form new blood 
vessels resulting in excessive lesion growth and this is further triggered by the release of angiogenic 
factors. Gallium-68 (68Ga) labeled arginine-glycine-aspartate tripeptide sequence (RGD) positron 
emission tomography (PET)/computed tomography (CT) imaging (68Ga-RGD PET/CT) may provide 
insight in the angiogenic status and treatment response of AVMs. This clinical feasibility study 
demonstrates that 68Ga-RGD PET/CT imaging can be used to quantitatively assess angiogenesis in 
peripheral AVMs.  
Methods: Ten patients with a peripheral AVM (mean age 40 years, four men, six women) and 
scheduled for endovascular embolization treatment, were prospectively included. All patients 
underwent 68Ga-RGD PET/CT imaging 60 min after injection (mean dose 207±5 MBq). Radiotracer 
uptake in AVM, blood-pool, and muscle activity were quantified as Standardized Uptake Values 
(SUVmax, SUVpeak) and descriptive analysis of the PET/CT images was performed. Furthermore, 
immunohistochemical analysis was performed on surgical biopsy material of peripheral AVMs to 
investigate the expression pattern of integrin αvβ3. 
Results: 68Ga-RGD PET/CT imaging showed enhanced radiotracer uptake in all AVM lesions (mean 
SUVmax 3.0±1.1; mean SUVpeak 2.2±0.9). Lesion/blood and lesion/muscle ratios were 3.5±2.2 and 
4.6±2.8, respectively. Radiotracer uptake in AVMs was significantly higher compared to uptake in 
background tissue (p=0.0006 and p=0.0014) for blood and muscle, respectively. Initial observations 
include identification of radiotracer uptake in (multifocal) AVM lesions and enhanced radiotracer 
uptake in intra-osseous components in those AVM cases affecting the bone integrity. 
Immunohistochemical analysis revealed cytoplasmatic and cell membranous integrin αvβ3 expression 
in endothelial cells of AVMs.  
Conclusion: This feasibility study showed increased radiotracer uptake in AVM with angiogenic 
activity compared to surrounding tissue without angiogenic activity, suggesting that 68Ga-RGD PET/CT 
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imaging can be used as a tool to quantitatively determine angiogenesis in AVM. Further studies will 
be conducted to explore the potential of 68Ga-RGD PET/CT imaging for guiding current treatment 
decisions and for assessment of response to anti-angiogenic treatment.  
KEY WORDS 
Arteriovenous malformation; PET/CT; RGD; integrin αvβ3; angiogenesis  
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INTRODUCTION 
Arteriovenous Malformations (AVMs) are tangles of shunting blood vessels (nidus), in which 
the arteries are directly connected to a venous drainage network (1). AVMs are highly complex 
structures, in which angiogenic stimuli act in dynamic interplay with local hemodynamic conditions 
(2,3). Patients commonly present with deformations, abnormal pulsating masses, pain, hemorrhage, 
or ulcers at ages ranging from young-to-middle age (4). When left untreated, loss of organ function, 
cardiac overload, skin necrosis, and/or bleeding are serious complications. AVMs can manifest 
throughout the body, but in particular for those patients with AVMs located in the face or 
extremities, the effect on quality of life of having respectively a severe cosmetic defect or reduced 
mobility can be devastating.  
Current treatment options of these congenital anomalies are still limited to either surgically 
remove the nidus or to occlude the nidus with endovascular embolization techniques. Unfortunately, 
both treatments have drawbacks and may show only partial response and/or severe damage to 
surrounding tissues (5,6). Furthermore, these interventions may cause hemodynamic changes to the 
AVM – initiating progression of disease at adjacent sites – resulting in increased complication risks, 
destabilization of the AVM, and a subsequent need for repeated interventions (6).  
Recent advances in the understanding of AVM-related angiogenesis has stimulated the 
discussion on the use of systemic drugs targeting angiogenesis (7,8). However, effective application 
of anti-angiogenic drugs to patients is hampered by the lack of accessible tools to assess the 
presence and dynamics of angiogenesis within the AVM during the course of the disease. Therefore, 
molecular imaging techniques enabling visualization of angiogenesis are warranted to provide 
clinicians with quantitative outcome measures that can be used to monitor follow-up of treatment 
efficacy or to predict response to (anti-angiogenic) therapy.  
Integrin αvβ3, expressed on activated endothelial cells of newly formed blood vessels, are an 
attractive target for radiopharmaceuticals allowing quantitative molecular imaging of angiogenesis 
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using radiolabeled arginine-glycine-aspartate tripeptide sequence (or RGD) derivatives and PET/CT 
(9,10). Gallium-68 labeled dimeric RGD (or 68Ga-RGD) is a radiopharmaceutical that binds integrin 
αvβ3 with high affinity and has shown its potential in tumor imaging (11-14). As the development of 
AVMs is closely related to angiogenesis, 68Ga-RGD PET/CT imaging may enable quantitative 
assessment of angiogenesis in peripheral AVMs. The aim of this study was to assess the integrin αvβ3 
expression levels in peripheral AVM and to determine the feasibility of 68Ga-RGD PET/CT imaging to 
visualize angiogenesis in peripheral AVMs.   
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MATERIALS AND METHODS 
Study Population 
This prospective proof-of-concept study was approved by the regional Ethics Review Board. 
The study (EudraCT 2015-005809-36) is registered in Dutch trial register, no. NL56104.091.16. 
Written informed consent was obtained from all individual participants included in this study. All 
procedures performed in this study were in accordance with the ethical standards of the institutional 
and national research committee and with the 1964 Helsinki declaration. 
Patients diagnosed with at least one peripheral AVM confined to the subcutaneous and/or 
muscle tissue, with or without an intraosseous component, were included. AVMs were classified by 
their flow dynamics, clinical behavior, and angioarchitecture according to the Yakes Classification 
(15). Patients were eligible if pre-operative imaging of the lesion (four-dimensional computed 
tomography angiography (4D-CTA) and angiographic imaging) were available, and patients were 
scheduled for percutaneous or transarterial embolization treatments with ethanol. Patients with 
contra-indications for 68Ga-RGD PET/CT imaging (pregnancy, breast-feeding, or severe 
claustrophobia), and/or an impaired renal- or liver function (creatinine clearance ≤60 ml/min, 
aspartate aminotransferase and alanine aminotransferase levels ≥3x upper limit of normal, and total 
bilirubin ≥2x upper limit of normal), were ineligible. When 68Ga-RGD PET/CT imaging was performed 
in between two treatments, imaging was scheduled at least six weeks after the last treatment to 
minimize potential radiotracer uptake related to treatment associated-inflammation. 
68Ga-RGD PET/CT Acquisition 
Patients were intravenously administered with 207±7 MBq, 42±8 µg 68Ga-RGD (range 197-
215 MBq and 34-58 µg respectively) using a slow bolus injection of 8 ml over 1 min. For radiotracer 
preparation see the description as provided in supplemental material 1. Patients had no restrictions 
in food or medicine intake, and were asked to void before scanning. At 61±6 min post injection, 68Ga-
RGD PET/CT images were acquired using a Siemens Biograph 40 mCT scanner (Siemens Healthcare). 
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A low-dose CT scan (512x512 voxels; 0.98x0.98x5 mm3 voxel size; 1 pitch; 16x1.2 mm) was acquired 
for attenuation correction and anatomical reference, with an automatically modulated x-ray tube 
voltage and current (120 kV, 50 mA) using Care kV and Care Dose4D (Siemens Healthcare). The PET 
images were acquired in list-mode with 10 min per bed position, with the field of view covering the 
entire arteriovenous malformation (200x200 matrix size; 4.07x4.07x5 mm3 voxel size; 2 to 3 
bedpositions (225-725 mm field-of-view covering)). The CT images were reconstructed with a B31f 
convolution kernel. The PET images were reconstructed using a 3D ordered-subset expectation 
maximization algorithm with a spatially varying point-spread function incorporating time-of-flight 
information; 3 iterations and 21 subsets; a 200x200 matrix (2.04 mm pixel size). A three-dimensional 
Gaussian filter kernel with a full-width-at-half-maximum of 3.0 mm and transaxial matrix size of 
200x200 mm was used as post reconstruction filter. 
 Safety analysis included the recording of adverse events according to Common Terminology 
Criteria for Adverse Events, version 4.03, recording of changes in vital signs (blood pressure, 
temperature, and heart rate) before and up to two hours after radiotracer injection, and included 
laboratory measurements, including hemocytology, kidney function (creatinine clearance, urea), and 
liver function (aspartate aminotransferase level, alanine aminotransferase level, total bilirubin), at 
baseline and one week after radiotracer injection. A study flowchart is provided in supplemental 
figure 1. 
68Ga-RGD PET/CT Image Analysis 
Visual image analysis and AVM detection was performed using Oasis Software (version 1.9; 
Segami Corporation, Columbia, MD, USA). PET quantification was performed with Inveon Research 
Workspace software (version 2.04; Siemens, Erlangen, Germany). When patients showed multiple 
AVMs, only the AVM that was or would be embolized was delineated. For radiotracer uptake in 
muscle and arterial tissue, a spherical volume of interest (VOI) with a 3 cm diameter was defined 
manually in CT images and subsequently transferred to the registered PET images. The segmentation 
of this VOI depended on the localization of the AVM and its surrounding tissue present within PET 
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field of view. For the relationship to intensity of uptake in areas with physiological radiotracer 
uptake, spherical VOIs in liver, spleen, mediastinum, and kidney were drawn. The information within 
all VOIs was subsequently exported to MATLAB version R2014b (MathWorks, Natick, MA, USA) to 
calculate maximum and peak standardized uptake values (SUVmax and SUVpeak). SUVpeak was 
determined using in-house developed software by generating a mean SUV of the voxel with highest 
uptake (SUVmax) and its surrounding voxels representing a sphere of 1 cm3. Lesion/blood- and 
lesion/muscle ratios were calculated as follows: 
𝑆𝑈𝑉𝑝𝑒𝑎𝑘,𝑙𝑒𝑠𝑖𝑜𝑛
𝑆𝑈𝑉𝑝𝑒𝑎𝑘,𝑏𝑙𝑜𝑜𝑑
 and 
𝑆𝑈𝑉𝑝𝑒𝑎𝑘,𝑙𝑒𝑠𝑖𝑜𝑛
𝑆𝑈𝑉𝑝𝑒𝑎𝑘,𝑚𝑢𝑠𝑐𝑙𝑒
, respectively. 
Immunohistochemical Analysis 
5-μm sections of frozen (n=3) and paraffin-embedded (n=7) surgical biopsy material from the 
lip, orbita, cheek, finger, foot, lower leg, and back of peripheral AVMs was used for 
immunohistochemical analysis. Tissue samples were stained for integrin αvβ3 expression (anti-αvβ3 
integrin monoclonal antibody, MAB1976B, clone LM609, 10 μg/ml, Merck Millipore (frozen sections) 
and AB7166, clone BV3, 1:100, Abcam (paraffin sections)), microvascular density (anti-CD31 
monoclonal antibody, 1:50, ab28364, Abcam), and hematoxylin-and-eosin. Evaluation by light 
microscopy was performed in which staining patterns, including the evaluation of the endothelium of 
vessels and/or normal tissues, were assessed.  
Statistical Analysis 
Values are represented as mean ± standard deviation. Graphs were made and statistical 
analyses of SUVpeak values were performed using GraphPad Prism 5.03 (Graph Pad Software, Inc, La 
Jolla, CA). Differences in background tissue uptake were tested for significance using a one-way 
ANOVA test with post hoc Bonferroni adjustments. Statistically significant differences between 
radiotracer uptake and background was tested using a paired sample t-test. An α-value of 0.05 was 
used in all analyses. Pattern of staining were scored semi-quantitatively according to staining 
intensity and extension in the whole slide (0: no staining; 1: weak staining; 2: moderate staining; 3: 
strong staining).  
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RESULTS 
Patient Population 
Six women and four men (mean age 43 y ± 17 and 34 y ± 8, respectively) participated in this 
pilot study. Patient characteristics are given in Table 1. One patient (#7) underwent 68Ga-RGD PET/CT 
imaging before first endovascular embolization therapy, four patients (#1, #2, #5, and #10) 
underwent 68Ga-RGD PET/CT imaging on average 2.5 months (range 2-3 months) after last treatment, 
three patients (#3, #8, and #9) were scheduled for a new treatment after nine months, due to 
underlying complications. One patient (#4) underwent 68Ga-RGD PET/CT imaging six months after the 
last intervention, but during the next intervention no nidus was found and therefore embolization 
could not be performed. One patient (#6) showed slowly progressive disease (increased pain) and 
underwent 68Ga-RGD PET/CT imaging before first embolization therapy after eight years.  
68Ga-RGD PET/CT Imaging Of AVM 
There were no adverse or clinically detectable injection-related (serious) adverse events nor 
any changes in vital signs in any of the subjects. No significant changes in vital signs were observed, 
and blood analysis before and one week after 68Ga-RGD tracer injection showed laboratory values 
within normal ranges, no clinically relevant changes were observed (data not shown). 
All lesions, as defined on conventional angiographic images, could be readily identified on 
68Ga-RGD PET/CT scans independently of the location or size of the AVM, with lesion/blood and 
lesion/muscle ratios of 3.5±2.2 and 4.6±2.8, respectively. In all patients radiotracer accumulation 
corresponded to the location of the nidus as defined by plain angiographic and 4D-CTA images (figure 
1). Mean SUVmax and SUVpeak of radiotracer uptake were 3.0 (range 1.0-4.6) and 2.2 (range 0.7-3.6) 
respectively. Uptake within the lesion was significantly higher than radioactivity levels in blood 
(p=0.0014) and muscle (p=0.0006). The uptake of 68Ga-RGD as defined with SUVpeak measurements in 
all AVMs and normal tissues are shown in figure 2. Radiotracer uptake in blood-pool and muscle was 
comparable in all patients even with variances in blood-pool and muscle selection. The mean 
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radiotracer uptake between blood-pool and muscle was not statistically significant different (p=0.11). 
An example of the range of physiological radiotracer uptake in different organs is provided in  
supplemental figure 2.   
In nine out of ten patients, the hotspots in the 68Ga-RGD PET/CT images co-localized with the 
center of the AVM as revealed on 4D-CTA and angiographic images. Interestingly, 68Ga-RGD PET/CT 
images revealed a PET-positive lesion within the palmar side of the right hand of patient #9, whereas 
angiographic imaging did show a diffuse and complex AVM with multiple enlarged feeding arteries 
and an increased venous drainage pattern. 
In contrast to the low variance in background tissue between the patients, a considerable 
variance in radiotracer uptake between patients within the AVM was observed (figure 2). Because all 
study subjects underwent 68Ga-RGD PET/CT imaging either before the first treatment or in between 
two treatments, an exploratory analysis of the correlation between therapy status and 68Ga-RGD 
uptake values was performed (supplemental figure 3).  
68Ga-RGD Uptake In Symptomatic And Asymptomatic Lesions 
According to the presence of patients’ pain symptoms at the location of the AVM nidus 
(symptomatic lesions), 68Ga-RGD PET/CT images revealed enhanced radiotracer uptake in the tissues 
adjacent to the nidus in five patients (patient #3, #6, #7, #8, and #10), suggesting uptake in 
asymptomatic lesions as well. In two patients (patient #6 and #8), this increased uptake 
corresponded to an additional nidus also observed on conventional imaging. However, in the other 
patients, these findings may indicate upregulated integrin αvβ3 expression through endothelial cell 
activation adjacent to the treated nidus, which could not be assessed by conventional imaging (white 
arrow in figure 3A and supplemental figure 4). High radiotracer uptake was also observed within the 
intra-osseous component of three AVMs (patient #3, #7, and #10), as indicated with the yellow arrow 
in figure 3B. Patient #3 previously suffered from an extensive symptomatic AVM in the distal part of 
the foot, which was treated with multiple embolization therapies. The 68Ga-RGD PET/CT images 
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showed significantly lower radiotracer uptake in the distal part of the foot as compared to the active 
nidus in the more proximal part, and a few persistent foci with enhanced activity around the toes 
(figure 1C), indicating reduced angiogenic activity after treatment. 
Immunohistochemical Analysis 
Integrin αvβ3 expression could be confirmed by immunohistochemical analysis of surgical 
AVM tissue. Cytoplasmatic and cell membranous integrin αvβ3 expression in endothelial cells of AVMs 
was observed, showing positive staining both for some arterial (scale 0-2) and venous endothelial 
cells (2) as correlated with endothelial cell staining with CD31. In addition, in some tissue samples, 
expression of integrin αvβ3 was observed on erythrocytes (0-2) and smooth muscle cells mainly of the 
vessel walls (scale 0-1). However, this staining was weak and background staining could not be 
excluded. A typical example of the immunostaining is given in figure 4.  
  
 
* 
* 
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DISCUSSION 
This proof-of-concept study showed the feasibility of 68Ga-RGD PET/CT imaging in peripheral 
AVMs. We demonstrated that 68Ga-RGD uptake is increased in the nidus in patients with AVMs and 
that this uptake can be readily detected with good contrast between lesion and background tissue. 
This allowed delineation of regions with and without enhanced integrin αvβ3 expression within an 
AVM.  
Although the integrin αvβ3 expression pattern and its role in tumors, wound healing, and 
chronic inflammation has already been shown (16-18), data on integrin αvβ3 expression and its role in 
AVM have been limited to cerebral vascular malformations (19). The angiogenic process in AVM is 
upregulated by pathologic and physiologic conditions, such as traumas, endothelial shear stress, and 
immune- or inflammatory stimuli (20,21). These conditions induce the expression of vascular 
endothelial growth factors (VEGF), cytokines (IL-6, TNF-α), and other endogenous modulators (such 
as HIF-1α), thereby enhancing migration and proliferation of endothelial and smooth-muscle cells, 
resulting in the formation of new blood vessels (21). Immunohistochemical analysis showed 
endothelial cell expression of αvβ3 integrins, however, a more extensive histological assessment is 
required to examine potential contributions of extracellular matrix remodeling through activated 
macrophages, which have been shown to also express αvβ3 integrins (22). The integrin αvβ3 
expression pattern on smooth muscle cells and erythrocytes are in line with previous publications 
(23). 
In patients with intra-osseous involvement, integrin αvβ3 was upregulated in those parts of 
the AVM that showed bone deformation. It is likely that this observed radiotracer uptake pattern in 
these patients is due to binding of 68Ga-RGD to integrin αvβ3 expressed both on osteoclasts and 
endothelial cells, because activated osteoclasts express high amounts of integrin αvβ3 to regulate cell-
matrix interactions and intracellular signals responsible for bone resorption (24). This finding may 
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have consequences for treatment approaches, especially in those patients that need clinical follow-
up to prevent pathological fractures.   
Although the number of patients included was relatively small, we have made some 
interesting observations as potential future applications of the use of 68Ga-RGD PET/CT in peripheral 
AVMs. 68Ga-RGD PET/CT identified additional foci of integrin αvβ3 expression in two patients as 
compared to conventional angiographic imaging and revealed a clear nidus in a complex AVM that 
was not revealed on conventional imaging. These 68Ga-RGD PET/CT findings may possibly have 
implications for treatment planning in those patients without a clear nidus visible on angiography, or 
in patients with a complex and/or large size AVM. Previous studies demonstrated that the lack of 
standardized and accurate interpretation of images from conventional imaging techniques in 
complex AVMs hamper correct diagnosis and accurate treatment planning (25). Furthermore, 4D-CTA 
and plain angiographic imaging provide detailed information on the extent and angioarchitecture of 
the AVM, but it will need further investigation whether 68Ga-RGD PET/CT could be used to evaluate 
the angiogenic status of AVMs that should be considered as therapeutic target.  
There are some limitations of the current feasibility study. Whereas  68Ga-labeled RGD 
derivatives showed favorable radiochemistry, radiolabeling properties, and tumour-to-normal tissue 
ratios (12), the image resolution of 68Ga-labeled radiotracers is in general inferior to 18F-labeled 
radiotracers (26). Furthermore, the contribution from non-specific uptake to 68Ga-RGD accumulation 
cannot be excluded, but as RGD radiotracers have shown a rapid clearance from the circulation, the 
enhanced permeability and retention effect is unlikely to play a major role in these lesions. Another 
limitation is that only one time point per patient was acquired. Therefore, an appropriate statistical 
analysis of the changes in angiogenesis pre- and post embolization was not feasible. Longitudinal 
68Ga-RGD PET/CT scans within the same patient – acquired in combination with conventional 
imaging, at baseline and during the course of embolization treatment – would be needed to 
investigate whether 68Ga-RGD PET/CT could predict response to therapy. 
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A few case reports have reported a role for novel anti-angiogenic therapeutics in the 
treatment of peripheral AVM (27-29). The expression of integrin αvβ3 in peripheral AVMs paves the 
way to further evaluate anti-angiogenic treatments for AVMs and the role of 68Ga-RGD PET/CT 
imaging in the development of these anti-angiogenic therapies. Besides, 68Ga-RGD PET/CT imaging 
may have the potential to provide quantitative information on the underlying pathogenesis of AVMs. 
New prospective clinical trials are warranted to determine how this novel imaging technique can 
improve our understanding of angiogenesis in AVM, and furthermore, how 68Ga-RGD PET/CT can be 
used to investigate its potential to personalize treatment of AVM patients.  
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CONCLUSION 
In this study, we demonstrated the feasibility of 68Ga-RGD PET/CT imaging to visualize 
integrin αvβ3 expression in peripheral AVM. It may provide important complementary information to 
conventional angiographic imaging and could potentially be a valuable tool for the assessment of 
angiogenesis. These findings stimulates further studies on the exact role of angiogenesis in AVM 
which are needed to study the potential role of 68Ga-RGD PET/CT imaging in the management of 
AVMs and/or guidance of treatments with novel drugs targeting angiogenesis. 
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KEY POINTS 
Question: Can 68Ga-RGD PET/CT imaging be used to visualize angiogenesis in peripheral 
arteriovenous malformations? 
Pertinent findings: This proof-of-concept study showed that 68Ga-RGD PET/CT enables the 
visualization of αvβ3 integrins in peripheral arteriovenous malformations. Tracer uptake in 
arteriovenous malformations was significantly higher compared to uptake in background tissue, with 
lesion/blood and lesion/muscle ratios of 3.5 ± 2.2 and 4.6 ± 2.8, respectively. 
Implications for patient care: Future studies may reveal whether 68Ga-RGD PET/CT may act as a 
complementary molecular imaging technique to the existing imaging modalities and may guide the 
application of novel anti-angiogenic drugs in peripheral AVMs.  
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TABLE 1: PATIENT CHARACTERISTICS. 
 
Pt no. 
(#) 
Age 
(y) 
Gender 
Yakes 
classification 
(15) 
Location arteriovenous 
malformation 
1 28 Male IIIb Chin 
2 27 Male II Nose 
3 44 Male II Right foot 
4 51 Female II Finger, digit I right 
5 64 Female II Finger, digit II right 
6 57 Female II Finger, digit V left 
7 38 Male IIIa Right lower leg 
8 26 Female II Left upper leg 
9 38 Female II Right hand 
10 23 Female II Right elbow 
 
 
 
 
 
 
 
 
  
RGD PET/CT in arteriovenous malformation   
23 
 
FIGURES 
 
FIGURE 1: 3D reconstructions of 4D-CTA (A,B) and 68Ga-RGD PET/CT (C) imaging of an arteriovenous 
malformation in the right foot of a male patient (44 y, #3). 3D reconstructions of 4D-CTA 
demonstrate an arterial input flow with the nidus indicated by the white circle (A) and venous 
outflow (D). Maximal intensity projection of 68Ga-RGD PET image at 60 min after injection, showing 
radiotracer uptake within the lesion (SUVmax 3.0; SUVpeak 2.3), as indicated by the arrow (B, E). The 
black and red lines indicate axial view of the 68Ga-RGD PET/CT images (C, F). This patient was 
previously treated with multiple embolizations for a symptomatic AVM in the distal part of the foot. 
The 68Ga-RGD PET/CT images show significantly lower radiotracer uptake and a few persistent foci 
with enhanced activity around the toes (E). Arterial and venous flow of this part is not shown in A 
and D. Abbreviations: SUV, standardized uptake value. 
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FIGURE 2: Scatter plot of peak standardized uptake values 
(SUVpeak) of arteriovenous malformation (AVM, mean 
2.2 ± 0.9), blood-pool (mean 0.8 ± 0.2), and muscle activity 
(mean 0.6 ± 0.2) of each individual patient. Significance levels: 
** P < 0.005; *** P < 0.001. ns = not significant. 
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FIGURE 3: Maximal intensity projection of 68Ga-RGD PET (A), CTA (B), fused axial 68Ga-RGD PET/CT 
(C), and 3D reconstruction of 4D-CTA (D) of a male patient (38 y, #7) showing a nidus in right leg 
arteriovenous malformation (SUVmax 3.2; SUVpeak 2.5, red arrows). The red line in (A) corresponds to 
axial slides of (B) and (C). Both a heterogeneous uptake pattern of enhanced radiotracer uptake in 
tissue adjacent to the nidus at the more proximal part of the right leg (white arrow in (A)) and a bone 
deformation in fibula caused by compression and infiltration of vessels could be visualized (yellow 
arrow in (B)). Furthermore, a large venous aneurysm (asterisk in (B)) was present. The 3D 
reconstruction of 4D-CTA (D) showed the arterial flow with the nidus and fistula (red arrow), and 
upcoming venous flow with the large venous aneurysm. Abbreviations: SUV, standardized uptake 
value.  
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FIGURE 4: Typical example of the immunohistochemical analysis for the evaluation of αvβ3 integrin 
expression of an arteriovenous malformation. The highlighted region in (A) shows the detailed 
hematoxylin-and-eosin (B), anti-CD31 (C), and anti-αvβ3 integrin (D) staining (scalebar denotes 100 
µm). CD31 staining demonstrated multiple small vessels within the field of view (C) and confirmed 
staining of αvβ3 integrin of these blood vessels (D). High-power magnification (50 µm) in (D) shows 
cell membranous αvβ3 integrin expression in endothelial cells of small blood vessels (black arrow, D). 
